Skip to main content
SpringerLink
Log in

Systemische Therapie kutaner Lymphome

Systemic treatment of cutaneous lymphomas

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Die Behandlung von Patienten mit primär kutanen Lymphomen erfordert zunächst eine sorgfältige Diagnostik zur Abgrenzung von nodalen Non-Hodgkin-Lymphomen mit kutanem Befall sowie eine genaue Zuordnung zum spezifischen Typ des Hautlymphoms, da die Prognose und Therapieoptionen von der präzisen Diagnose abhängen. Für die meisten kutanen Lymphome sind in den frühen Stadien zunächst hautgerichtete Lokaltherapien zur Krankheitskontrolle ausreichend. In den fortgeschrittenen Stadien sowie bei aggressiveren kutanen Lymphomen wie dem diffus großzelligen B-Zell-Lymphom oder der leukämischen Variante des kutanen T-Zell-Lymphoms, dem Sézary-Syndrom, sind von Beginn an Systemtherapien indiziert. Die aktuellen Empfehlungen zur Systemtherapie kutaner Lymphome werden in der vorliegenden Arbeit zusammengefasst.

Abstract

The management of patients with primary cutaneous lymphomas requires first of all a diagnostic work-up in order to differentiate between patients with nodal non-Hodgkin lymphomas with cutaneous manifestations and those with primary cutaneous lymphomas. In the latter an exact diagnosis of the type of cutaneous lymphoma has to be determined due to varying prognoses between the types of primary cutaneous lymphomas. In general, cutaneous lymphoma patients in early stages of disease can be treated successfully with skin-directed therapies. More advanced stages and some aggressive types like primary cutaneous diffuse large B-cell lymphoma, leg type or the leukemic variant of cutaneous T-cell lymphoma, the Sézary syndrome, require systemic treatment. The current recommendations regarding systemic therapy of patients with primary cutaneous lymphomas are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bradford PT, Devesa SS, Anderson WF, Toro JR (2009) Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 113:5064–5073

    Article  PubMed  CAS  Google Scholar 

  2. Willemze R, Jaffe ES, Burg G et al (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768–3785

    Article  PubMed  CAS  Google Scholar 

  3. Jenni D, Karpova MB, Seifert B et al (2010) Primary cutaneous lymphoma: two-decade comparison in a population of 263 cases from a Swiss tertiary referral centre. Br J Dermatol 2010 Nov 16 [Epub ahead of print]

  4. Assaf C, Gellrich S, Steinhoff M et al (2007) Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges 5:662–668

    Article  PubMed  Google Scholar 

  5. Demierre MF, Gan S, Jones J, Miller DR (2006) Significant impact of cutaneous T-cell lymphoma on patients‘ quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 107:2504–2511

    Article  PubMed  Google Scholar 

  6. Kaye FJ, Bunn PA Jr, Steinberg SM et al (1989) A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321:1784–1790

    Article  PubMed  CAS  Google Scholar 

  7. Stadler R, Assaf C, Klemke CD et al (2008) Short German guidelines: cutaneous lymphomas. J Dtsch Dermatol Ges 6(Suppl 1):S25–S31

    Article  PubMed  Google Scholar 

  8. Senff NJ, Noordijk EM, Kim YH et al (2008) European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112:1600–1609

    Article  PubMed  CAS  Google Scholar 

  9. Trautinger F, Knobler R, Willemze R et al (2006) EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 42:1014–1030

    Article  PubMed  Google Scholar 

  10. Gellrich S, Muche JM, Pelzer K et al (2001) Anti-CD20 antibodies in primary cutaneous B-cell lymphoma. Initial results in dermatologic patients. Hautarzt 52:205–210

    Article  PubMed  CAS  Google Scholar 

  11. Morales AV, Advani R, Horwitz SM et al (2008) Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol 59:953–957

    Article  PubMed  Google Scholar 

  12. Valencak J, Weihsengruber F, Rappersberger K et al (2009) Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol 20:326–330

    Article  PubMed  CAS  Google Scholar 

  13. Gronbaek K, Moller PH, Nedergaard T et al (2000) Primary cutaneous B-cell lymphoma: a clinical, histological, phenotypic and genotypic study of 21 cases. Br J Dermatol 142:913–923

    Article  PubMed  CAS  Google Scholar 

  14. Hoefnagel JJ, Vermeer MH, Jansen PM et al (2005) Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol 141:1139–1145

    Article  PubMed  CAS  Google Scholar 

  15. Sah A, Barrans SL, Parapia LA et al (2004) Cutaneous B-cell lymphoma: pathological spectrum and clinical outcome in 51 consecutive patients. Am J Hematol 75:195–199

    Article  PubMed  CAS  Google Scholar 

  16. Stanway A, Rademaker M, Kennedy I, Newman P (2004) Cutaneous B-cell lymphoma of nails, pinna and nose treated with chlorambucil. Australas J Dermatol 45:110–113

    Article  PubMed  Google Scholar 

  17. Bailey EM, Ferry JA, Harris NL et al (1996) Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. Am J Surg Pathol 20:1011–1023

    Article  PubMed  CAS  Google Scholar 

  18. Bekkenk MW, Vermeer MH, Geerts ML et al (1999) Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. J Clin Oncol 17:2471–2478

    PubMed  CAS  Google Scholar 

  19. Zinzani PL, Quaglino P, Pimpinelli N et al (2006) Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 24:1376–1382

    Article  PubMed  Google Scholar 

  20. Dreno B (2006) Standard and new treatments in cutaneous B-cell lymphomas. J Cutan Pathol 33(Suppl 1):47–51

    Article  PubMed  Google Scholar 

  21. Kodama K, Massone C, Chott A et al (2005) Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 106:2491–2497

    Article  PubMed  CAS  Google Scholar 

  22. Senff NJ, Hoefnagel JJ, Jansen PM et al (2007) Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 25:1581–1587

    Article  PubMed  Google Scholar 

  23. Grange F, Maubec E, Bagot M et al (2009) Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. Arch Dermatol 145:329–330

    Article  PubMed  CAS  Google Scholar 

  24. Guyot A, Ortonne N, Valeyrie-Allanore L, Bagot M (2010) Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients. Arch Dermatol 146:89–91

    Article  PubMed  Google Scholar 

  25. Wobser M, Kneitz H, Brocker EB, Becker JC (2011) Primary cutaneous diffuse large B-cell lymphoma, leg-type, treated with a modified R-CHOP immunochemotherapy – diagnostic and therapeutic challenges. J Dtsch Dermatol Ges 3:204–211

    Google Scholar 

  26. Fenot M, Quereux G, Brocard A et al (2010) Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type. Eur J Dermatol 20:753–757

    PubMed  CAS  Google Scholar 

  27. Kobold S, Killic N, Lutkens T et al (2010) Isolated limb perfusion with melphalan for the treatment of intractable primary cutaneous diffuse large B-cell lymphoma leg type. Acta Haematol 123:179–181

    Article  PubMed  Google Scholar 

  28. Kaehler KC, Egberts F, Hauschild A (2010) Electrochemotherapy in symptomatic melanoma skin metastases: intraindividual comparison with conventional surgery. Dermatol Surg 36:1200–1202

    Article  PubMed  CAS  Google Scholar 

  29. Park SI, Press OW (2007) Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol 14:632–638

    Article  PubMed  Google Scholar 

  30. Di Bella NJ, Khan MM, Dakhil SR et al (2003) Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin’s lymphoma: a phase II multicenter study. Clin Lymphoma 3:235–240

    Article  Google Scholar 

  31. Bunn PA, Jr, Foon KA, Ihde DC et al (1984) Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 101:484–487

    PubMed  Google Scholar 

  32. Olsen EA (2003) Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 16:311–321

    Article  PubMed  Google Scholar 

  33. Booken N, Weiss C, Utikal J et al (2010) Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sezary syndrome. J Dtsch Dermatol Ges 8:428–438

    PubMed  Google Scholar 

  34. Zackheim HS, Kashani-Sabet M, Hwang ST (1996) Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 34:626–631

    Article  PubMed  CAS  Google Scholar 

  35. Aviles A, Nambo MJ, Neri N et al (2007) Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sezary syndrome. Cancer Biother Radiopharm 22:836–840

    Article  PubMed  CAS  Google Scholar 

  36. Farol LT, Hymes KB (2004) Bexarotene: a clinical review. Expert Rev Anticancer Ther 4:180–188

    Article  PubMed  CAS  Google Scholar 

  37. Duvic M, Martin AG, Kim Y et al (2001) Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137:581–593

    PubMed  CAS  Google Scholar 

  38. Duvic M, Hymes K, Heald P et al (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19:2456–2471

    PubMed  CAS  Google Scholar 

  39. Assaf C, Bagot M, Dummer R et al (2006) Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 155:261–266

    Article  PubMed  CAS  Google Scholar 

  40. Gniadecki R, Assaf C, Bagot M et al (2007) The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 157:433–440

    Article  PubMed  CAS  Google Scholar 

  41. Eklund JW, Kuzel TM (2005) Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther 5:33–38

    Article  PubMed  CAS  Google Scholar 

  42. Jones D, Ibrahim S, Patel K et al (2004) Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy. Clin Cancer Res 10:5587–5594

    Article  PubMed  CAS  Google Scholar 

  43. Nakase K, Kita K, Nasu K et al (1994) Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol 46:179–183

    Article  PubMed  CAS  Google Scholar 

  44. Eriksen KW, Kaltoft K, Mikkelsen G et al (2001) Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 15:787–793

    Article  PubMed  CAS  Google Scholar 

  45. Prince HM, Duvic M, Martin A et al (2010) Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 28:1870–1877

    Article  PubMed  CAS  Google Scholar 

  46. Olsen E, Duvic M, Frankel A et al (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376–388

    PubMed  CAS  Google Scholar 

  47. Foss F, Demierre MF, DiVenuti G (2005) A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 106:454–457

    Article  PubMed  CAS  Google Scholar 

  48. Olsen EA, Kim YH, Kuzel TM et al (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109–3115

    Article  PubMed  CAS  Google Scholar 

  49. Whittaker SJ, Demierre MF, Kim EJ et al (2010) Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28(29):4485–4491

    Article  PubMed  CAS  Google Scholar 

  50. Lundin J, Hagberg H, Repp R et al (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101:4267–4272

    Article  PubMed  CAS  Google Scholar 

  51. Lenihan DJ, Alencar AJ, Yang D et al (2004) Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 104:655–658

    Article  PubMed  CAS  Google Scholar 

  52. Lundin J, Kennedy B, Dearden C et al (2005) No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome. Blood 105:4148–4149

    Article  PubMed  CAS  Google Scholar 

  53. Bernengo MG, Quaglino P, Comessatti A et al (2007) Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica 92:784–794

    Article  PubMed  CAS  Google Scholar 

  54. Kim YH, Duvic M, Obitz E et al (2007) Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109:4655–4662

    Article  PubMed  CAS  Google Scholar 

  55. Zinzani PL, Baliva G, Magagnoli M et al (2000) Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 18:2603–2606

    PubMed  CAS  Google Scholar 

  56. Jidar K, Ingen-Housz-Oro S, Beylot-Barry M et al (2009) Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. Br J Dermatol 161:660–663

    Article  PubMed  CAS  Google Scholar 

  57. Wollina U, Dummer R, Brockmeyer NH et al (2003) Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98:993–1001

    Article  PubMed  CAS  Google Scholar 

  58. Duarte RF, Schmitz N, Servitje O, Sureda A (2008) Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant 41:597–604

    Article  PubMed  CAS  Google Scholar 

  59. Klemke CD, Goerdt S, Schrama D, Becker JC (2006) New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas. J Dtsch Dermatol Ges 4:395–406

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Vortragshonorare und Reisekostenunterstützung durch die Firmen Cephalon und Therakos.

Author information

Authors and Affiliations

  1. Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Mannheim, Medizinische Fakultät der Ruprecht-Karls-Universität Heidelberg, Theodor-Kutzer-Ufer 1–3, 68135, Mannheim, Deutschland

    C.-D. Klemke

Authors
  1. C.-D. Klemke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C.-D. Klemke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klemke, CD. Systemische Therapie kutaner Lymphome. Hautarzt 62, 436–443 (2011). https://doi.org/10.1007/s00105-010-2043-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-010-2043-3

Schlüsselwörter

Keywords

Search

Navigation